Maastricht-based cultivated meat startup Mosa Meat has secured an additional €15 million in funding to fuel its next phase of regulatory market approvals and first significant revenue generation. This financing round was supported by Invest-NL (backed by a guarantee from InvestEU), LIOF, PHW Group, and Jitse Groen, founder and CEO of Just Eat Takeaway.com.Victor Meijer, investment principal at InvestNL, said, “Cultivated meat is an important component in the protein transition needed to reduce the impact of ...

Core Insights - Pluri, Inc. has entered significant international collaborations through its foodtech and agtech subsidiaries, marking a major advancement in its mission to transform food and agriculture production using advanced 3D cell-expansion technology [1][2][3] Company Overview - Pluri operates three subsidiaries: Ever After Foods, Kokomodo, and Coffeesai, which have signed collaboration agreements with global leaders in food and agtech across Asia, Europe, and the U.S. This expansion indicates increasing commercial viability and global demand for sustainable, cell-based innovations [2][4] - The collaborations are anchored by a minimum-viable-product (MVP) funded by leading global players, showcasing substantial commitment and trust in the innovative potential of these partnerships [4] Subsidiary Developments - Ever After Foods is advancing scale-up validation and pre-commercial trials with food companies, focusing on turning pipeline projects into pilot results while maintaining a capital-efficient business model [5] - Kokomodo has signed strategic agreements with a European food innovation firm and a U.S.-based multinational, aiming to enhance its research, development, and manufacturing capabilities in the cacao industry [5] - Coffeesai has entered a collaboration with a major East Asian food and beverage conglomerate to accelerate eco-friendly coffee production through cell-based cultivation, minimizing the environmental impact of traditional farming [5] Market Context - The momentum of Pluri's initiatives comes at a time of rising demand for sustainable solutions in agriculture, driven by challenges such as climate change, dwindling natural resources, and a growing global population [3][4] - Pluri's proprietary 3D cell expansion platform enables rapid scaling of next-generation food and agriculture solutions with significantly reduced environmental footprints, addressing global challenges in sustainable food production and climate resilience [6]

Core Insights - ImpacFat has officially expanded into Japan, establishing a shared laboratory and office in Tokyo, marking its first international move outside of Singapore [1][4]. Company Overview - ImpacFat is recognized as the first company globally to cultivate omega-3-rich fat from fish stem cells, eliminating common contaminants found in wild-caught fish [2][10]. - The startup was founded in 2019 by Mandy Hon and Dr. Shigeki Sugii, originating from the Institute of Molecular and Cell Biology at Singapore's A*STAR [7][8]. Strategic Partnerships - The expansion in Japan is in collaboration with East Japan Railway Company JR East, with plans to set up at Link Scholar's Hub (LiSH) in Takanawa Gateway City [4][5]. - Key investments from both Japanese and Singaporean investors are aimed at accelerating innovation in sustainable food ingredients, supplements, and cosmetics [5]. Market Positioning - ImpacFat aims to contribute to Japan's food security, sustainable development, and marine biodiversity protection [5]. - The company emphasizes the importance of fats in cultivated meats, addressing a gap in the market that many startups have overlooked [9]. Production and Cost Challenges - The startup faces challenges in scaling production due to high costs associated with cell-based technology, which requires biomedical-grade products [11]. - To mitigate costs, ImpacFat is producing components in-house, although this approach demands time and patience [12]. Future Outlook - The expansion into Japan is expected to provide access to strategic industrial expertise and commercialization networks, facilitating the company's progress toward global market entry [14].

Core Insights - Pluri Inc. aims to lead a global biotech revolution in healthcare, food, and agriculture through its innovative cell expansion platform, which allows for the production of pharmaceuticals, food products, and agricultural goods to address multi-billion dollar markets [1][10] Business Developments - The company anticipates a significant turning point in the upcoming fiscal year by unlocking the potential of its cell expansion technology, particularly in the cocoa and coffee industries, which are facing shortages due to climate change and rising demand [2][9] - Pluri has strengthened its position in the cultivated cacao space by partnering with an Israeli AgFoodTech company that is developing cell-based cacao technology, addressing challenges in the global cacao industry [3][10] - The company has secured additional investment from a new strategic partner with expertise in healthcare, enhancing its financial position and ability to expand into key geographies [4][10] Financial Performance - In the first nine months of fiscal year 2025, Pluri recorded a fourfold increase in revenue, rising from $230,000 in the same period of fiscal year 2024 to $938,000, driven by its CDMO and AgTech businesses [7][8] - The company is advancing new food tech partnerships and licensing opportunities, contributing to its revenue growth [8][10] Strategic Initiatives - Pluri holds a 69% stake in Ever After Foods Ltd., which utilizes its cell expansion technology for cultivated meat production, with significant funding rounds supporting this initiative [5][10] - The company is actively discussing commercial implementation opportunities with leading players in the cocoa and coffee industries, including potential out-licensing to strategic partners [9][10] Research and Development - Pluri has received $2.2 million in funding from the U.S. National Institutes of Health and the Department of Defense for the development of PLX-R18 for treating Acute Radiation Syndrome, although this funding has been discontinued due to federal budget cuts [6][10]

As filed with the Securities and Exchange Commission on November 7, 2023 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Steakholder Foods Ltd. (Exact name of registrant as specified in its charter) Not Applicable (Translation of Registrant's name into English) State of Israel 2000 Not applicable (I.R.S. Employer Identification No.) 5 David Fikes St., P.O. Box 4061 Rehovot, Israel 7638205 Tel +972 73-332-2853 (Address, ...

Amendment No. 2 As filed with the Securities and Exchange Commission on January 5, 2023 Registration No. 333-268559 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 To FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 STEAKHOLDER FOODS LTD. (Exact Name of Registrant as Specified in its Charter) (State or Other Jurisdiction of Incorporation or Organization) State of Israel 2000 Not Applicable (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Ident ...